Literature DB >> 33835971

Low Frequency of Acute Pancreatitis in Hospitalized COVID-19 Patients.

Edoardo Troncone1, Silvia Salvatori1, Giorgia Sena1, Elena De Cristofaro1, Norma Alfieri1, Irene Marafini1, Carla Paganelli2, Renato Argirò3, Diana Giannarelli4, Giovanni Monteleone1, Giovanna Del Vecchio Blanco1.   

Abstract

OBJECTIVE: The clinical significance of increased serum pancreatic enzymes (PEs) in coronavirus disease 2019 (COVID-19) patients has not yet been fully understood. We aimed to investigate the frequency and the impact on clinical outcome of PE elevation and acute pancreatitis in such patients.
METHODS: Clinical data, laboratory tests, and cross-sectional images were analyzed from COVID-19 patients admitted to the Tor Vergata Hospital in Rome. Variables associated with PE abnormalities, intensive care unit (ICU) admission, or death were investigated through univariate and multivariate analyses and Cox proportional hazard model.
RESULTS: Pancreatic enzymes were available in 254 of 282 COVID-19 patients. Among these, 66 patients (26%) showed mild elevation of PE, and 11 patients (4.3%) had severe elevation (>3 times of the upper limit of normal). Overall, 2 patients met the diagnostic criteria for acute pancreatitis. Hepatic and renal involvements were associated with PE elevation. Multivariate analysis showed that mild and severe PE elevations were significantly associated with ICU admission (odds ratios, 5.51 [95% confidence interval, 2.36-12.89; P < 0.0001] and 26.2 [95% confidence interval, 4.82-142.39; P < 0.0001]).
CONCLUSIONS: Increase in serum PE, but not acute pancreatitis, is frequent in hospitalized COVID-19 patients and associates with ICU admission.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Year:  2021        PMID: 33835971     DOI: 10.1097/MPA.0000000000001770

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  5 in total

Review 1.  Review on acute pancreatitis attributed to COVID-19 infection.

Authors:  Takumi Onoyama; Hiroki Koda; Wataru Hamamoto; Shiho Kawahara; Yuri Sakamoto; Taro Yamashita; Hiroki Kurumi; Soichiro Kawata; Yohei Takeda; Kazuya Matsumoto; Hajime Isomoto
Journal:  World J Gastroenterol       Date:  2022-05-21       Impact factor: 5.374

2.  Prevalence and Outcomes of Pancreatic Enzymes Elevation in Patients With COVID-19: A Meta-Analysis and Systematic Review.

Authors:  You Zhou; Yu-Tong Ge; Xiao-Xi Yang; Qian Cai; Yan-Bing Ding; Liang-Hao Hu; Guo-Tao Lu
Journal:  Front Public Health       Date:  2022-05-12

3.  COVID-19 induces new-onset insulin resistance and lipid metabolic dysregulation via regulation of secreted metabolic factors.

Authors:  Xi He; Chenshu Liu; Jiangyun Peng; Zilun Li; Fang Li; Jian Wang; Ao Hu; Meixiu Peng; Kan Huang; Dongxiao Fan; Na Li; Fuchun Zhang; Weiping Cai; Xinghua Tan; Zhongwei Hu; Xilong Deng; Yueping Li; Xiaoneng Mo; Linghua Li; Yaling Shi; Li Yang; Yuanyuan Zhu; Yanrong Wu; Huichao Liang; Baolin Liao; Wenxin Hong; Ruiying He; Jiaojiao Li; Pengle Guo; Youguang Zhuo; Lingzhai Zhao; Fengyu Hu; Wenxue Li; Wei Zhu; Zefeng Zhang; Zeling Guo; Wei Zhang; Xiqiang Hong; Weikang Cai; Lei Gu; Ziming Du; Yang Zhang; Jin Xu; Tao Zuo; Kai Deng; Li Yan; Xinwen Chen; Sifan Chen; Chunliang Lei
Journal:  Signal Transduct Target Ther       Date:  2021-12-16

4.  Prevalence and prognosis of increased pancreatic enzymes in patients with COVID-19: A systematic review and meta-analysis.

Authors:  Feng Yang; Yecheng Xu; Yinlei Dong; Yuting Huang; Yunting Fu; Tian Li; Chenyu Sun; Sanjay Pandanaboyana; John A Windsor; Deliang Fu
Journal:  Pancreatology       Date:  2022-03-25       Impact factor: 3.977

5.  SARS-CoV-2 and the pancreas: What do we know about acute pancreatitis in COVID-19 positive patients?

Authors:  Giuseppe Brisinda; Maria Michela Chiarello; Giuseppe Tropeano; Gaia Altieri; Caterina Puccioni; Pietro Fransvea; Valentina Bianchi
Journal:  World J Gastroenterol       Date:  2022-09-28       Impact factor: 5.374

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.